OncLive TV

Julie N. Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses treatment for patients with high-risk metastatic disease following the FDA approval of abiraterone acetate (Zytiga).

Mark D. Tyson, MD, urologic oncologist, Mayo Clinic, discusses 2 trials that have shaped physicians’ opinions on the use of neoadjuvant chemotherapy in patients with bladder cancer.

Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses the role of blinatumomab (Blincyto) for patients with minimal residual disease (MRD)-positive acute lymphoblastic leukemia (ALL).

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses pegylated recombinant human hyaluronidase (PEGPH20) in pancreatic adenocarcinoma.

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, reflects on some of the most pivotal FDA approvals in acute leukemia in the past year.

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in chronic lymphocytic leukemia.

Parminder Singh, MD, Hematologist/Oncologist, Mayo Clinic, discusses treatment selection for patients with bladder cancer. At this point, patient selection is based on the approval or labeling indications of the drug, where the patient lies in the spectrum of disease, and whether or not they have any alternative options.

Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses common molecular subtype and phenotype alterations in the epigenetic pathway that are used to predict response to treatment.

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, Department of Lymphoma, John Theurer Cancer Center, discusses combination strategies with immunotherapy for patients with hematologic malignancies.

Stuart L. Goldberg, MD, chief medical officer, John Theurer Cancer Center, discusses precision medicine for patients with hematologic malignancies.

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses recent advancements with biosimilars.

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of the ELIANA trial in acute lymphoblastic leukemia (ALL).

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses antibody drug conjugates in the treatment of patients with triple-negative breast cancer.

Stephen J. Freedland, MD, director, Center for Integrated Research in Cancer and Lifestyle, co-director, Cancer Genetics and Prevention Program, associate director, Faculty Development Samuel Oschin Comprehensive Cancer Institute, professor of surgery, Cedars-Sinai Medical Center, discusses nuanced diet and lifestyle interventions in patients with prostate cancer.

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses developing and available imaging modalities in prostate cancer.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the tolerability and toxicity of immune-oncology agents in kidney cancer.

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses the future of detection in metastatic castration-resistant prostate cancer (mCRPC).

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.

Jason J. Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses noncutaneous melanoma.

Stephen J. Schuster, MD, professor of hematology/oncology at the University of Pennsylvania Abramson Cancer Center, discusses CAR T-cell therapy in diffuse large B-cell lymphoma.

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses toxicities in the treatment of patients with multiple myeloma.

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses challenges for patients with gastrointestinal stromal tumors (GIST).

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the tolerability of PARP inhibitors for patients with ovarian cancer.

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the importance of individualized approaches in the use of abiraterone (Zytiga) versus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Erik P. Castle, MD, professor of urology, Mayo Clinic, discusses the use of adjuvant versus early salvage therapy in patients with prostate cancer, citing his own preference for early salvage therapy.

Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the combination of ibrutinib (Imbruvica) plus nivolumab (Opdivo) in non-Hodgkin lymphoma.

Aiwu Ruth He, MD, PhD, associate professor of medicine, Georgetown-Lombardi Comprehensive Cancer Center, discusses the future of precision medicine in gastrointestinal malignancies.

Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, reflects on recent data in advanced colorectal cancer.

Daniel J. DeAngelo, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses ongoing trials of patients with acute myeloid leukemia (AML).

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses enzalutamide (Xtandi) for patients with nonmetastatic castration-resistant prostate cancer.